公开(公告)号：US20200377509A1

公开(公告)日：2020-12-03

申请号：US16497141

申请日：2018-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  SCOHIA PHARMA, INC

Inventor： Seiji MIWATASHI ,  Yasufumi MIYAMOTO ,  Koji WATANABE ,  Yayoi NAKAYAMA ,  Yuko HITOMI ,  Jumpei AIDA ,  Nobuyuki TAKAKURA ,  Hideki FURUKAWA ,  Naoyoshi NOGUCHI ,  Yasuhiro HIRATA ,  Shizuo KASAl ,  Toshitake KOBAYASHI ,  Tsuyoshi MAEKAWA ,  Satoshi SASAKI ,  Shigemitsu MATSUMOTO

IPC: C07D491/052 ,  C07D401/12 ,  C07D401/14 ,  C07D211/22

Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.

公开(公告)号：US20210115048A1

公开(公告)日：2021-04-22

申请号：US16608723

申请日：2018-04-26

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuji KITAMURA ,  Zenichi IKEDA ,  Minoru IKOMA ,  Koji WATANABE ,  Hideki HIROSE ,  Takafumi YUKAWA ,  Sachie MORIMOTO ,  Naoki NISHIZAWA ,  Taiji ASAMI

IPC: C07D487/04 ,  A61P9/04 ,  A61K47/38 ,  A61K31/4184 ,  A61K9/48 ,  A61K9/20

Abstract: The present invention provides a compound or a salt thereof having a calcium-sensing receptor antagonistic activity, and being expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like. The compounds represented by formula (I) or a salt thereof has a calcium-sensing receptor antagonistic activity, and is expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like, wherein each symbol is as described in the specification.

公开(公告)号：US20200039957A1

公开(公告)日：2020-02-06

申请号：US16499432

申请日：2018-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Seiji MIWATASHI ,  Yasufumi MIYAMOTO ,  Koji WATANABE ,  Yayoi NAKAYAMA ,  Yuko HITOMI ,  Jumpei AIDA ,  Nobuyuki TAKAKURA ,  Hideki FURUKAWA ,  Naoyoshi NOGUCHI ,  Yasuhiro HIRATA ,  Kazuaki TAKAMI ,  Norihito TOKUNAGA ,  Tomohiro OKAWA ,  Akita SHIBUYA ,  Shizuo KASAl ,  Toshitake KOBAYASHI ,  Tsuyoshi MAEKAWA

IPC: C07D401/12 ,  C07D211/22 ,  C07D401/14 ,  C07C59/72 ,  C07D213/64 ,  C07D401/10 ,  C07D413/10

Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.

公开(公告)号：US20160115128A1

公开(公告)日：2016-04-28

申请号：US14898633

申请日：2014-08-08

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Jumpei AIDA ,  Yayoi YOSHITOMI ,  Yuko HITOMI ,  Naoyoshi NOGUCHI ,  Yasuhiro HIRATA ,  Hideki FURUKAWA ,  Akito SHIBUYA ,  Koji WATANABE ,  Yasufumi MIYAMOTO ,  Tomohiro OKAWA ,  Nobuyuki TAKAKURA ,  Seiji MIWATASHI

IPC: C07D211/34 ,  C07D413/10 ,  C07D401/14 ,  C07D405/12 ,  C07D413/14 ,  C07D401/10 ,  C07D401/12

CPC classification number: C07D211/34 ,  C07D211/22 ,  C07D213/30 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/10 ,  C07D413/14

Abstract: Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.

Abstract translation: 提供具有GPR40激动剂活性和GLP-1促分泌作用的新型芳环化合物。 由下式表示的化合物：其中每个符号如说明书所述，或其盐具有GPR40激动剂活性和GLP-1促分泌素作用，可用于预防或治疗癌症，肥胖症，糖尿病，高血压， 高脂血症，心力衰竭，糖尿病并发症，代谢综合征，肌肉减少症等，具有优异的疗效。